Matuzumab Biosimilar - Research Grade

Tikum, A.F. Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates. Pharmaceutics 2022, 14, 1917.

Human

EGFR

1.0 - 5.0 mg/ml

Human IgG1

Humanized

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Detects human EGFR. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Matuzumab.

Blue ice

As a key regulator of epithelial cell growth, the epidermal growth factor receptor (EGFR) has long been a target in solid-tumour research. This research-grade anti-human EGFR recombinant monoclonal antibody is an unconjugated, non-therapeutic analog of matuzumab, designed around the EGFR target for research use only. Produced to in vivo standards as an ultra-pure, low-endotoxin human IgG1, it is supplied in scalable milligram to gram quantities to support high-throughput and bulk laboratories. It serves as a reliable control and active reagent across preclinical work, including receptor-blocking assays, in vitro screening, in vivo tumour models, and antibody-drug conjugate development.

Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, ERBB, ERBB1, HER1

P00533

ICH3001-100ml ICH3002-100ml ICH3003-100ml

https://www.imgt.org/mAb-DB/